about
Few and far between: how HIV may be evading antibody avidityExtensive complement-dependent enhancement of HIV-1 by autologous non-neutralising antibodies at early stages of infectionSevere anaemia is not associated with HIV-1 env gene characteristics in Malawian childrenGlycan masking of Plasmodium vivax Duffy Binding Protein for probing protein binding function and vaccine developmentThe Global HIV/AIDS Vaccine Enterprise: scientific strategic planAntibody vs. HIV in a clash of evolutionary titansNeutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infectionComprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodiesSelection, transmission, and reversion of an antigen-processing cytotoxic T-lymphocyte escape mutation in human immunodeficiency virus type 1 infectionA lectin isolated from bananas is a potent inhibitor of HIV replicationPolyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individualsThe aftermath of the Merck's HIV vaccine trialStructural definition of a conserved neutralization epitope on HIV-1 gp120Evolution of subtype C HIV-1 Env in a slowly progressing Zambian infant.SIVsm quasispecies adaptation to a new simian host.Virion Glycoprotein-Mediated Immune Evasion by Human Cytomegalovirus: a Sticky Virus Makes a Slick GetawayDeterminants of the Bovine Leukemia Virus Envelope Glycoproteins Involved in Infectivity, Replication and PathogenesisCurrent Advances in Virus-Like Particles as a Vaccination Approach against HIV InfectionThe HIV glycan shield as a target for broadly neutralizing antibodiesCloak and Dagger: Alternative Immune Evasion and Modulation Strategies of PoxvirusesRecent strategies targeting HIV glycans in vaccine designStructural insights on the role of antibodies in HIV-1 vaccine and therapyDesigning synthetic vaccines for HIVAntibody responses to envelope glycoproteins in HIV-1 infectionDesign Challenges for HIV-1 Vaccines Based on Humoral ImmunityHIV-1 neutralizing antibodies: understanding nature's pathwaysThe Antibody Response against HIV-1Antibodies in HIV-1 vaccine development and therapyViral quasispecies evolutionOrigin of the transmitted virus in HIV infection: infected cells versus cell-free virusHIV-1 antibodies from infection and vaccination: insights for guiding vaccine designThe hepatitis C virus glycan shield and evasion of the humoral immune responseVirological features associated with the development of broadly neutralizing antibodies to HIV-1Generation of neutralizing antibodies and divergence of SIVmac239 in cynomolgus macaques following short-term early antiretroviral therapyStructure-based stabilization of HIV-1 gp120 enhances humoral immune responses to the induced co-receptor binding siteAntigenic properties of the human immunodeficiency virus envelope glycoprotein gp120 on virions bound to target cellsStructural plasticity and conformational transitions of HIV envelope glycoprotein gp120Impaired antibody response causes persistence of prototypic T cell-contained virusMiniCD4 microbicide prevents HIV infection of human mucosal explants and vaginal transmission of SHIV(162P3) in cynomolgus macaquesAntigenic subversion: a novel mechanism of host immune evasion by Ebola virus
P2860
Q21090507-F4E17265-9598-44A9-9F2C-382072BA29B4Q21245045-73C701BF-004A-4ACA-B092-AF7EC487D97AQ21261525-2CB99945-DC83-45A6-BF30-86F30D649829Q21558777-5EE8F2D5-BA42-4FA7-80C6-FAE847D6ECB0Q21563445-EA6C47F8-7C3C-4031-BB1A-E3754F77F2ACQ24536059-C61F6F6E-D571-4120-913A-1037ED6D99C7Q24538985-007531EF-E39B-469A-B990-AD7B0E36C022Q24561905-A0C3A8E7-60C7-4D4C-85AD-F54ADB59D18AQ24564623-2EA3B65C-6A0A-425B-A7B2-71571F798B93Q24629155-51E5137A-8AA5-4B34-8E78-2FE153B68C27Q24635002-C9146DCE-89CD-432C-9B79-9ED3E5806B5DQ24654458-203C2A26-EC62-4627-9025-ACA7E7B5D84BQ24655948-80743830-6D89-414A-8084-9CA2FEA622E5Q24815687-131B53A0-01D2-4B72-B299-50CE3B760EA6Q24817181-1089AD64-CCD7-4EE3-A801-5BE6646653F5Q26745798-4E144023-DEDD-4E14-8429-CBF168FBCC59Q26749621-AB69F80F-E098-4D2F-9947-1915E4906659Q26775082-8E3BF9F0-3138-4FFA-91DF-1BD1D14EF4CCQ26786540-957672BF-E07E-4636-A145-9536CB7814ADQ26797325-B4DAB2B9-7746-4B31-8667-2EA385B43C4FQ26823603-E8490A3C-F7D5-4A5E-BF81-E5AB3941CC0EQ26829461-88017CBB-9C90-49A8-ABE1-57CDA0701B41Q26862617-57CE11A0-D5DB-48B2-941B-E2639FC27786Q26991572-4A93A2C4-5EE8-4F01-9989-740E1225C612Q26991829-84676D0E-0164-488C-93E1-3B9664D3A705Q27000480-C99CAA90-A804-40CF-BA0D-156D19EBE9ABQ27000889-50FB07F0-677C-4629-98F1-B60B4750D9F7Q27011574-D8C9F05F-B249-4030-9A71-1CEB914C2F4BQ27013917-C56AB6CF-85E3-4B44-AA00-4783DC7419E4Q27021279-9F307B41-A593-4801-BFB6-395E4430592CQ27022055-AD4FE273-377C-4EDD-89E9-1F9EBB3D4663Q27023390-9E5997E3-D7EA-4962-B18A-809A6F9F849EQ27025177-8F2837F0-F900-4022-B9CA-A1A64BE9EB31Q27313556-34B81858-68E5-4956-BDC5-D6D7052DCA64Q27316899-C75BE0E8-A396-443C-BCF2-03D74F2C69FFQ27320687-BAB0F8F3-5AF6-4B52-BF15-7108B485ADC1Q27327645-C2EDBF8E-A425-4FA7-B2ED-1B11D6362CF7Q27331309-8588D435-2FA6-4CC2-9192-218040CBEF72Q27339377-587FD3CF-8989-45C9-AC80-D0A966B6BDCFQ27339643-10EF5398-C901-4CC8-8443-DCD5C72CE998
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մարտին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Antibody neutralization and escape by HIV-1
@ast
Antibody neutralization and escape by HIV-1
@en
type
label
Antibody neutralization and escape by HIV-1
@ast
Antibody neutralization and escape by HIV-1
@en
prefLabel
Antibody neutralization and escape by HIV-1
@ast
Antibody neutralization and escape by HIV-1
@en
P2093
P50
P3181
P356
P1433
P1476
Antibody neutralization and escape by HIV-1
@en
P2093
Huxiong Hui
John C Kappes
Julie M Decker
Maria G Salazar
Martin A Nowak
Michael S Saag
Natalia L Komarova
Peter D Kwong
Shuyi Wang
Xiaoyun Wu
P2888
P304
P3181
P356
10.1038/NATURE01470
P407
P577
2003-03-01T00:00:00Z
P5875
P6179
1053047116